The Upcoming PCAC Meeting The FDA notice confirms that the PCAC will convene this summer to evaluate whether to recommend the following seven bulk drug substances for inclusion on the 503A bulks list: July 23, 2026: BPC-157 (free base / acetate) KPV (free base / acetate) Thymosin Beta-4, Fragment (LKKTETQ) (TB-500) (free base / acetate) MOTs-C (free base / acetate) July 24, 2026: Emideltide (DSIP) (free base / acetate) Semax (free base / acetate) Epitalon (free base / acetate) All seven substances are of considerable interest to compounding pharmacies, prescribers, and patients
Takami, M
Meanwhile, in Ayadas study involving 9,808,677 individuals, MAFLD showed a prevalence of over 33.0%, attracting significant attention [4, 5]
Our data suggest that the tested drug combinations induce cell death in MNA cells through two mechanisms: inhibition of OXPHOS and cell cycle arrest
10.1007/s11892-022-01453-4 36 OuyangX.DaiY.WenJ
7 BakhtiariM.PanahiY.AmeliJ.DarvishiB
